Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study

BACKGROUND: Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy. We evaluated the response to ACT in combination with interferon alpha (IFNa) preconditioning in patients with stage IV metastatic melanoma, most of which were progressive on cytotoxic T-lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Verdegaal, Els, van der Kooij, Monique K, Visser, Marten, van der Minne, Caroline, de Bruin, Linda, Meij, Pauline, Terwisscha van Scheltinga, Anton, Welters, Marij J, Santegoets, Saskia, de Miranda, Noel, Roozen, Inge, Liefers, Gerrit Jan, Kapiteijn, Ellen, van der Burg, Sjoerd H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174065/
https://www.ncbi.nlm.nih.gov/pubmed/32238469
http://dx.doi.org/10.1136/jitc-2019-000166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174065/
https://www.ncbi.nlm.nih.gov/pubmed/32238469
http://dx.doi.org/10.1136/jitc-2019-000166

Ejemplares similares